Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

The Methuselah Debates

Technology Review’s most widely read – and most controversial – story in 2005 was a profile of Aubrey de Grey, an English bioinformaticist and self-educated biogerontologist who has outlined a seven-point plan to cure human aging (see Do You Want to Live Forever?, February). The story provoked reams of criticism, from both de Grey’s supporters and his detractors. The former, who approve of de Grey’s quest to defeat death – known as “strategies for engineered negligible senescence,” or SENS – were outraged by Technology Review’s skeptical tone. At the other end of the spectrum, traditional biogerontologists were annoyed that de Grey’s ideas were getting any press at all.

Prior to the debate in our pages (both print and online), few scientists in the field had come out against de Grey – who has become one of the world’s most quoted anti-aging scientists. After the story, in November 2005, molecular biology journal EMBO reports published a letter signed by approximately 30 scientists explaining why de Grey’s popularity is detrimental to the goals of anti-aging research.

“We as journalists and scientists have a duty to present this in a critical framework,” says Jason Pontin, editor in chief of Technology Review. “Biogerontology matters because geriatrics matters, now more than ever. Anything we can do to create therapies so people can live a long, healthy life until the end – that will be the great accomplishment of biogerontology.” (Also see our Q&A with Leonard Guarente, December 2005/January 2006.)

In September, Pontin issued the SENS challenge, a $20,000 prize to any molecular biologist or group of molecular biologists who could satisfactorily explain why the SENS plan wouldn’t work. Technology Review has received several entries and will announce a winner early next year.

A healthful new year to all our readers.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me